Results 51 to 60 of about 333,932 (156)

Use of Glucose‐Lowering Drugs for Type 2 Diabetes Among Danish Care Home Residents

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Care home admission often reflects frailty and limited life expectancy, potentially altering the benefit‐harm balance of glucose‐lowering drug (GLD) treatment for type 2 diabetes (T2D). Real‐world data on treatment patterns in this setting remain limited. We examined GLD use for T2D among Danish care home residents.
Hanin Harbi, Reimar W. Thomsen, Carina Lundby, Jacob Volmer Stidsen, Kurt Højlund, Jesper Ryg, Mette Reilev, Anton Pottegård   +7 more
wiley   +1 more source

Heart failure in cardiorenal syndromes

Терапевтический архив, 2013
This review considers the classification of cardiorenal syndromes (CRS), the pathogenesis of heart failure, and a search for therapeutic targets for its treatment, biomarkers for heart and kidney failure, difficulties in therapy and reversion of the ...
E P Kharchenko
doaj  

A 52‐Week Efficacy and Safety Study of Teneligliptin, as an Add‐On to Empagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus: A Randomised, Double‐Blind, Placebo‐Controlled Phase 3 Trial (TERA305 Study)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the long‐term efficacy and safety of teneligliptin add‐on in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and empagliflozin. Materials and Methods In this randomised, double‐blind, phase 3 trial, 214 patients received teneligliptin 20 mg (n = 107) or placebo (n = 107) once daily for 24 ...
Jun Sung Moon, Kyung Ah Han, Dong‐Lim Kim, Sang Yong Kim, Soo‐Kyung Kim, Bon Jeong Ku, Woo Je Lee, Tae Keun Oh, Ji A Seo, Sang‐Ah Chang, Moon‐Kyu Lee, Kyu Jeung Ahn, Chul Sik Kim, Tae Nyun Kim, Bong‐Soo Cha   +14 more
wiley   +1 more source

SGLT2 Inhibitors and Cardiovascular Outcomes in Patients With Fabry Disease: Observations From a Federated Research Network

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background and Aim Fabry disease (FD) is frequently complicated by renal impairment and cardiovascular events; however, evidence on sodium–glucose cotransporter‐2 inhibitors (SGLT2i) in this population is scarce. Accordingly, we assessed the association between SGLT2i exposure and cardiovascular outcomes in adults with FD. Methods We conducted
Leandra Serio, Michele Rossi, Amir Askarinejad, Enrico Tartaglia, Tommaso Bucci, Enrica Marrone, Dinesh K. Kalra, Claudio Ferri, Gregory Y. H. Lip   +8 more
wiley   +1 more source

Nocturnal LUTS made easy for office urologists: how should we diagnose and treat from a lifelong perspective?

Continence Reports
Background: Nocturnal lower urinary tract symptoms (LUTS), including enuresis, nocturia, and nocturnal incontinence, present differently across the lifespan, with growing relevance of cardiorenal contributors in later life.
Laure Van de Steen, Mauro Van den Ende, Irina Verbakel, Andries Van Huele, Anne-Françoise Spinoit, Herman Depypere, Patrick Calders, Anton De Spiegeleer, An Mariman, Dirk Vogelaers, Karlien Dhondt, Lien Dossche, Jeffrey Weiss, George Bou Kheir, Jason Lazar, Ann Raes, Erik Van Laecke, François Hervé, Karel Everaert   +18 more
doaj   +1 more source

Nephroprotective Effects of the Dual GCGR/GLP‐1R Agonist Survodutide in Hypertension‐Accelerated Diabetic Kidney Disease

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Survodutide is a novel long‐acting dual glucagon (GCGR)/glucagon‐like peptide‐1 (GLP‐1R) receptor agonist currently in phase‐3 clinical development for the treatment of people living with obesity and metabolic dysfunction‐associated steatohepatitis.
Alexander Hamilton, Louise Thisted, Maria Ougaard, Max Hahn, Kasper Andersen, Johanna Perens, Robert Augustin, Besnik Bajrami, Wolfgang Rist, Michael Christensen, Henrik H. Hansen, Thomas Klein   +11 more
wiley   +1 more source

Supplemental material - Syringaresinol inhibits cardiorenal fibrosis through HSP90 in a cardiorenal syndrome type 2

, 2023
Supplemental material for Syringaresinol inhibits cardiorenal fibrosis through HSP90 in a cardiorenal syndrome type 2 by Jianjie Wang, Jianqin Zou, Cheng Zhao, Han Yu, Jiajia Teng and Lei Dong in Human & Experimental Toxicology ...
Lei Dong (165252), Han Yu (110573), Jianqin Zou (14837068), Jianjie Wang (436616), Cheng Zhao (2535307), Jiajia Teng (14837071)   +5 more
core   +1 more source

GLP‐1–Based Therapy in Type 1 Diabetes: Balancing Efficacy, Safety, and Patient Selection

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To critically examine the evolving evidence on glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and the dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1 receptor agonist tirzepatide as adjuncts to insulin therapy in type 1 diabetes (T1D), with particular emphasis on their benefit–risk balance in individuals with ...
Thales Rossatto, Ricardo de Andrade Oliveira, Andréia Machado Cardoso   +2 more
wiley   +1 more source

Neuropsychiatric Outcomes Associated With GLP‐1 Receptor Agonist Use in Medicare Beneficiaries With Type 2 Diabetes: Variation by Treatment Pattern and Obesity Status

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Glucagon‐like peptide‐1 (GLP‐1) receptors are expressed in brain regions governing mood, reward and stress, yet the neuropsychiatric effects of GLP‐1 receptor agonist (GLP‐1 RA) therapy remain poorly characterized. We estimated associations between GLP‐1 RA use and neuropsychiatric disorders and variation by obesity status and treatment ...
Seo Hyon Baik, Fitsum Baye, Haotian Xian, Kin Wah Fung, Clement J. McDonald   +4 more
wiley   +1 more source

Continuum [PDF]

, 2020
'Continuum' is a project which is a part of Sophie Stone's PhD research into 'Multiplicity as a Process of Experimental Music'. This folder comprises all documentation for 'Continuum', including images, scores, and video and audio ...
Stone, S.
core